As filed with the Securities and Exchange Commission on March 15, 2005
Registration No. 333-_____
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM S-8
INTROGEN THERAPEUTICS, INC.
| Delaware (State or other jurisdiction of incorporation or organization) |
74-2704230 (I.R.S. Employer Identification Number) |
301 Congress Avenue, Suite 1850
Austin, Texas 78701
(512) 708-9310
(Address, including zip code, and telephone number, including area code, of
Registrant’s principal executive offices)
2000 STOCK OPTION PLAN
(Full title of the plan)
David G. Nance
Chief Executive Officer
INTROGEN THERAPEUTICS, INC.
301 Congress Avenue, Suite 1850
Austin, Texas 78701
(512) 708-9310
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copy to:
Christopher J. Ozburn, Esq.
Wilson Sonsini Goodrich & Rosati
Professional Corporation
8911 Capital of Texas Highway N.
Westech 360, Suite 3350
Austin, TX 78759-7247
CALCULATION OF REGISTRATION FEE
| Proposed | Proposed | |||||||||||||||
| Amount | Maximum | Maximum | Amount of | |||||||||||||
| of Shares to be | Offering | Aggregate | Registration | |||||||||||||
| Title of Securities to be Registered | Registered (1) | Price Per Share (2) | Offering Price | Fee | ||||||||||||
2000 Stock Option Plan Common
Stock, $0.001 par value (options
available for future grant) |
1,531,140 | $ | 6.96 | $ | 10,656,734.40 | $ | 1,254.30 | |||||||||
| (1) | This Registration Statement shall also cover any additional shares of Common Stock which become issuable under the 2000 Stock Option Plan by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration that results in an increase in the number of the Registrant’s outstanding shares of Common Stock. |
| (2) | The proposed maximum offering price per share has been estimated in accordance with Rule 457(c) under the Securities Act of 1933, as amended (the “Securities Act”) as to the 1,531,140 additional shares of Common Stock authorized for issuance pursuant to the 2000 Stock Option Plan, solely for the purpose of calculating the registration fee. No options have been granted with respect to such shares. The computation is based upon the average of the high and low price of the Common Stock as reported on the Nasdaq National Market on March 9, 2005, because the price at which the options to be granted in the future may be exercised is not currently determinable. |
| PART II | ||||||||
| Item 8. Exhibits. | ||||||||
| SIGNATURES | ||||||||
| POWER OF ATTORNEY | ||||||||
| INDEX TO EXHIBITS | ||||||||
| Opinion of Counsel | ||||||||
| Consent of Independent Registered Public Accounting Firm | ||||||||
INTROGEN THERAPEUTICS, INC.
REGISTRATION STATEMENT ON FORM S-8
STATEMENT UNDER GENERAL INSTRUCTION E — REGISTRATION OF ADDITIONAL SECURITIES
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,531,140 shares of the Registrant’s Common Stock to be issued pursuant to the Registrant’s 2000 Stock Option Plan (the “Plan”). The contents of (i) the Registrant’s Form S-8 Registration Statement filed with the Securities and Exchange Commission on March 5, 2004 (Commission File No. 333-113299) relating to the Plan, (ii) the Registrant’s Form S-8 Registration Statement filed with the Securities and Exchange Commission on April 23, 2003 (Commission File No. 333-104697) relating to the Plan, (iii) the Registrant’s Form S-8 Registration Statement filed with the Securities and Exchange Commission on February 4, 2002 (Commission File No. 333-82122) relating to the Plan, and (iv) the Registrant’s Form S-8 Registration Statement filed with the Securities and Exchange Commission on April 10, 2001 (Commission File No. 333-58648) relating to the Plan (collectively, the “Filed Form S-8’s”), including periodic filings updating or amending the contents of the Filed Form S-8’s, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.
PART II
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 8. Exhibits.
The Exhibits listed on the accompanying Index to Exhibits are filed as part hereof, or incorporated by reference into, this Registration Statement. (See Index to Exhibits below)
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant, Introgen Therapeutics, Inc., certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Austin, State of Texas, on March 15, 2005.
| INTROGEN THERAPEUTICS, INC. |
||||
| By: | /s/ DAVID G. NANCE | |||
| David G. Nance | ||||
| Chief Executive Officer | ||||
II-4
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David G. Nance and James W. Albrecht, Jr., and each of them, his attorneys-in-fact, each with the power of substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED, THIS REGISTRATION STATEMENT ON FORM S-8 HAS BEEN SIGNED BY THE FOLLOWING PERSONS IN THE CAPACITIES AND ON THE DATES INDICATED.
| Signature | Title | Date | ||
/s/ DAVID G. NANCE
David G. Nance |
Chief Executive Officer and President (Principal Executive Officer) | March 15, 2005 | ||
| /s/ JAMES W. ALBRECHT, JR.
James W. Albrecht, Jr. |
Chief Financial Officer (Principal Financial and Accounting Officer) | March 15, 2005 | ||
| /s/ JOHN N. KAPOOR, PH.D.
John N. Kapoor, Ph.D. |
Chairman of the Board and Director | March 15, 2005 | ||
| /s/ WILLIAM H. CUNNINGHAM, PH.D.
William H. Cunningham, Ph.D. |
Director | March 15, 2005 | ||
| /s/ S. MALCOLM GILLIS, PH.D.
S. Malcolm Gillis, Ph.D. |
Director | March 15, 2005 | ||
| /s/ PETER BARTON HUTT
Peter Barton Hutt |
Director | March 15, 2005 | ||
| /s/ CHARLES E. LONG
Charles E. Long |
Director | March 15, 2005 |
II-5
INTROGEN THERAPEUTICS, INC.
REGISTRATION STATEMENT ON FORM S-8
INDEX TO EXHIBITS
| Exhibit | ||
| No. | Description | |
5.1
|
Opinion of counsel as to legality of securities being registered. | |
(1) 10.1
|
2000 Stock Option Plan. | |
23.1
|
Consent of Independent Registered Public Accounting Firm. | |
23.3
|
Consent of counsel (contained in Exhibit 5.1). | |
24.1
|
Power of Attorney (see page II-5). |
| (1) | Incorporated by reference to Exhibit 10.3 filed with Registrant’s Registration Statement on Form S-1 (File No. 333-30582), as amended. |
II-6